Khristenko Vladimir

Khristenko Vladimir

Biography

2015: President of Nanolek

In 2015, Vladimir Khristenko took over as president of the Russian biopharmaceutical company Nanolek.

2022: Resignation as President of Nanolek

Nanolek co-founder Vladimir Khristenko announced his resignation from the presidency, which he has held since 2015. This was announced on December 29, 2022 by Zdrav.Expert representatives of the Nanolek company. He transferred the full leadership of the pharmaceutical company - the supplier of 25% of vaccines for the national vaccination calendar of Russia - to his partner, General Director of Nanolek Mikhail Nekrasov. The composition of the company's shareholders remains unchanged.

Vladimir Khristenko

"I consider my mission fulfilled: our company has gone from the phase of a clean startup to the status of one of the backbone companies in Russian biopharmaceuticals," said Vladimir Khristenko. - On average, for Russian business 12 years is a lot, but for pharma - very little. We developed ahead of the curve, at record speeds. "

According to him, the company's revenue increased from 300 million rubles. in 2015 to almost 20 billion rubles. in 2021. In 2020, revenue growth of 70% was recorded compared to 2019, and in 2021 - + 57% compared to 2020.

"For Nanolek, the time has come to move to the next level, which requires a different management style than mine," said Vladimir Khristenko. "I'm definitely a startup person. My element is creating something from scratch, with maximum risks, but also with maximum drive. Over the past few years, I have tried to invest pointwise in other people's endeavors. It's quite interesting, too, but I understand for sure that I don't have much of it. So I will translate the spirit, reflex what was done and achieved, and be sure to come up with something new. "

Being one of the co-founders of Nanolek, Mikhail Nekrasov remains its general director. One of the pioneers of the "new Russian pharma," a doctor by education and a successful entrepreneur in the field of biotechnology, he will continue to work on business development. As noted in the company, there are many prospects for growth in connection with the urgent task of intensive import substitution. During its work, Nanolek has accumulated competencies for this task, working with world market leaders in localization projects.

"The main task of the coming years is the development of strategic partnerships with major players in the Russian market," stressed Mikhail Nekrasov. - The state sets ambitious tasks for the whole pharmacy: in order to provide citizens with access to the necessary medicines and means of disease prevention, it is important, first of all, import substitution, but not only - it is also necessary to develop promising work on the creation of its own innovative drugs. All this is impossible without close cooperation of pharmaceutical companies - we will need to go shoulder to shoulder and learn how to effectively combine resources. "